Isolated monoclonal anti-repulsive guidance molecule A antibodies and uses thereof
First Claim
Patent Images
1. An isolated monoclonal anti-Repulsive Guidance Molecule a (“
- RGMa”
) antibody that comprises a variable heavy chain region comprising a complementarity determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO;
2, a CDR2 comprising the amino acid sequence of SEQ ID NO;
3, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
4, and a variable light chain region comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
6, a CDR2 comprising the amino acid sequence of SEQ ID NO;
7, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
8 or of SEQ ID NO;
73.
2 Assignments
0 Petitions
Accused Products
Abstract
Provided herein are anti-Repulsive Guidance Molecule a (RGMa) antibodies and methods of using the antibodies to treat and diagnose neurite degenerative diseases and disorders.
276 Citations
11 Claims
-
1. An isolated monoclonal anti-Repulsive Guidance Molecule a (“
- RGMa”
) antibody that comprises a variable heavy chain region comprising a complementarity determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO;
2, a CDR2 comprising the amino acid sequence of SEQ ID NO;
3, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
4, and a variable light chain region comprising a CDR1 comprising the amino acid sequence of SEQ ID NO;
6, a CDR2 comprising the amino acid sequence of SEQ ID NO;
7, and a CDR3 comprising the amino acid sequence of SEQ ID NO;
8 or of SEQ ID NO;
73. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11)
- RGMa”
Specification